472 related articles for article (PubMed ID: 25325851)
1. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Haddock LJ; Ramsey DJ; Young LH
Semin Ophthalmol; 2014; 29(5-6):257-62. PubMed ID: 25325851
[TBL] [Abstract][Full Text] [Related]
2. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
[TBL] [Abstract][Full Text] [Related]
3. Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
Moshfeghi AA
Semin Ophthalmol; 2011 May; 26(3):139-48. PubMed ID: 21609227
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
5. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
[TBL] [Abstract][Full Text] [Related]
6. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
[TBL] [Abstract][Full Text] [Related]
7. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
[TBL] [Abstract][Full Text] [Related]
8. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
[TBL] [Abstract][Full Text] [Related]
9. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.
Chaudhary KM; Romero JM; Ezon I; Fastenberg DM; Deramo VA
Retina; 2013; 33(7):1407-16. PubMed ID: 23492945
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
[TBL] [Abstract][Full Text] [Related]
11. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
12. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
[TBL] [Abstract][Full Text] [Related]
13. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
[TBL] [Abstract][Full Text] [Related]
15. Safety of bilateral intravitreal injections delivered in a teaching institution.
Chao DL; Gregori NZ; Khandji J; Goldhardt R
Expert Opin Drug Deliv; 2014 Jul; 11(7):991-3. PubMed ID: 24815986
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
17. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
Inman ZD; Anderson NG
Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
[TBL] [Abstract][Full Text] [Related]
18. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE
Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994
[TBL] [Abstract][Full Text] [Related]
19. Endophthalmitis after anti-VEGF injections.
Klein KS; Walsh MK; Hassan TS; Halperin LS; Castellarin AA; Roth D; Driscoll S; Prenner JL
Ophthalmology; 2009 Jun; 116(6):1225.e1. PubMed ID: 19486799
[No Abstract] [Full Text] [Related]
20. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
